Apparent Diffusion Coefficient Value and Ratio as Noninvasive Potential Biomarkers to Predict Prostate Cancer Grading: Comparison With Prostate Biopsy and Radical Prostatectomy Specimen

被引:77
作者
De Cobelli, Francesco [1 ,2 ]
Ravelli, Silvia [1 ,2 ]
Esposito, Antonio [1 ,2 ]
Giganti, Francesco [1 ,2 ]
Gallina, Andrea [3 ]
Montorsi, Francesco [3 ]
Del Maschio, Alessandro [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Radiol, I-20132 Milan, Italy
[2] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Ctr Expt Imaging, I-20132 Milan, Italy
[3] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Urol, I-20132 Milan, Italy
关键词
apparent diffusion coefficient; apparen diffusion coefficient ratio; diffusion-weighted imaging; Gleason score; prostate cancer; ACTIVE SURVEILLANCE; GLEASON SCORES; ADC VALUES; 3-T MRI; MEN; CONCORDANCE; MORTALITY; CARCINOMA; ANTIGEN; TRENDS;
D O I
10.2214/AJR.14.13146
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
100231 [临床病理学]; 100902 [航空航天医学];
摘要
OBJECTIVE. The purpose of this study is to test the association between diffusion-weighted MRI and prostate cancer Gleason score at both biopsy and final pathologic analysis after radical prostatectomy. SUBJECTS AND METHODS. Patients with prostate cancer (n = 72) underwent diffusion- weighted MRI (b values, 0, 800, and 1600 s/mm(2)) with an endorectal coil. Apparent diffusion coefficient (ADC) and ADC ratio were obtained in normal and pathologic tissue and were correlated with transrectal ultrasound-guided biopsy (n = 72) and histopathologic (n = 39) Gleason scores using the ANOVA test. ADC accuracy was estimated using ROC curves. RESULTS. Lesions suspicious for prostate cancer were detected in 65 patients. The mean ADC was 1.47 and 0.87 x 10(-3) mm(2)/s for normal and pathologic tissue, respectively (p < 0.001). When we divided the population into four groups (normal tissue and biopsy Gleason scores of 6, 7, and 8-10), then the mean ADC value was 1.47, 0.96, 0.80, and 0.78 x 10(-3) mm(2)/s, respectively (p < 0.001). The ADC ratio decreased along with an increase in biopsy Gleason score (66.9%, 56.7%, and 51.5% for Gleason scores of 6, 7 and 8-10, respectively) (ANOVA, p = 0.003) and pathologic Gleason score (ANOVA, p < 0.001). ROC curves had an AUC of 0.94 and 0.86 for ADC and ADC ratio, respectively (p = 0.012 and 0.042, respectively). CONCLUSION. Decreasing ADC values may represent a strong risk factor of harboring a poorly differentiated prostate cancer, independently of biopsy characteristics.
引用
收藏
页码:550 / 557
页数:8
相关论文
共 40 条
[1]
Imaging of prostate cancer [J].
Akin, Oguz ;
Hricak, Hedvig .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2007, 45 (01) :207-+
[2]
[Anonymous], 2018, American Joint Committee on Cancer Cancer Staging Manual
[3]
ESUR prostate MR guidelines 2012 [J].
Barentsz, Jelle O. ;
Richenberg, Jonathan ;
Clements, Richard ;
Choyke, Peter ;
Verma, Sadhna ;
Villeirs, Geert ;
Rouviere, Olivier ;
Logager, Vibeke ;
Futterer, Jurgen J. .
EUROPEAN RADIOLOGY, 2012, 22 (04) :746-757
[4]
Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications [J].
Bastian, Patrick J. ;
Carter, Ballentine H. ;
Bjartell, Anders ;
Seitz, Michael ;
Stanislaus, Peter ;
Montorsi, Francesco ;
Stief, Christian G. ;
Schroeder, Fritz .
EUROPEAN UROLOGY, 2009, 55 (06) :1321-1332
[5]
Radical prostatectomy versus watchful waiting in early prostate cancer [J].
Bill-Axelson, A ;
Holmberg, L ;
Ruutu, M ;
Häggman, M ;
Andersson, SO ;
Bratell, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Garmo, H ;
Palmgren, J ;
Adami, HO ;
Norlén, BJ ;
Johansson, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :1977-1984
[6]
The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management [J].
Cooperberg, MR ;
Lubeck, DP ;
Meni, MV ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2141-2149
[7]
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[8]
PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[9]
Etzioni R, 2002, J NATL CANCER I, V94, P981
[10]
Mortality at 120 days after prostatic biopsy:: A population-based study of 22,175 men [J].
Gallina, Andrea ;
Suardi, Nazareno ;
Montorsi, Francesco ;
Capitanio, Umberto ;
Jeldres, Claudio ;
Saad, Fred ;
Graefen, Markus ;
Shariat, Shahrokh F. ;
Widmer, Hugues ;
Arjane, Philippe ;
Peloquin, Francois ;
Perrotte, Paul ;
Karakiewicz, Pierre I. .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (03) :647-652